# KLOW Peptide Dosage — Research Context for KPV, GHK-Cu, BPC-157 and TB-500

> KLOW peptide dosage: the canonical 80 mg vial composition, component-level research doses by species and route, and the pharmacokinetic mismatch that makes a single 'KLOW dose' undefined.

The canonical KLOW vial is 80 mg across four components. No validated human dosing exists for the blend — this board reads the component literature and names every gap.

## Before the numbers

KLOW peptide dosage is not a single figure. The blend is a co-formulation of four peptides — KPV, GHK-Cu, BPC-157 and TB-500 — each with its own research-dose range, its own route of administration, its own half-life, and its own evidence base. Because no controlled study has tested the blend, no dose optimization exists for KLOW as a unit. The numbers on this page describe what each component was administered at in the studies that produced its research record. They are not recommendations, protocols, or validated human doses. 'Take X' language does not appear on this board.

## KLOW peptide dosage — the canonical vial

The most widely cited research-vial composition across independent compounders is:

- **GHK-Cu: 50 mg** (the mass-dominant component, ~62.5% of total)
- **BPC-157: 10 mg**
- **TB-500: 10 mg**
- **KPV: 10 mg**
- **Total: 80 mg** (lyophilized, reconstituted with bacteriostatic water for laboratory handling)

No FDA-approved or pharmacopeial KLOW combination product exists. The 80 mg / 50/10/10/10 split is a research-use convention, not a pharmacopeial standard. Different compounders may supply different ratios.

## KLOW dosage

The four constituent doses in the canonical vial are derived from component-level research, not from a validated blend dose-finding study. The component research doses — in species-appropriate terms — are as follows.

**KPV** (MW 342.44 Da, CAS 67727-97-3): In DSS-induced colitis in C57BL/6 mice, oral KPV was administered at 100 micromolar in drinking water [3]. In vitro activity was seen at nanomolar concentrations in human epithelial cells [3]. No validated human dose exists.

**GHK-Cu** (MW 402.92 Da, CAS 89030-95-5): Gene-expression modulation in fibroblasts observed at 1–10 nM in vitro [5]. Topical formulations have been used in placebo-controlled clinical cosmetic studies; systemic doses in humans have not been established for approved indications.

**BPC-157** (MW 1419.53 Da, CAS 137525-51-0): In rat Achilles tendon studies, intraperitoneal doses of 10 micrograms, 10 nanograms and 10 picograms per rat were studied [2]. In the 2025 IV safety pilot, two adults received 10 mg on day 1 and 20 mg on day 2 (in 250 cc saline, 1-hour infusion) with no adverse events observed [6]. In the interstitial cystitis pilot and intra-articular series, doses are not fully specified in the abstracts; the knee pain series used intra-articular injection [11, 15].

**TB-500 / thymosin beta-4**: In the rat wound model, topical and intraperitoneal thymosin beta-4 was active; as little as 10 picograms stimulated keratinocyte migration [1]. In the Phase 1 safety study, full-length thymosin beta-4 was given intravenously to healthy adults at 42, 140, 420 or 1260 mg with dose-proportional PK and no dose-limiting toxicities [9]. The TB-500 heptapeptide fragment has not been studied separately in equivalent dose-ranging work.

## KLOW peptide dosage and frequency — the pharmacokinetic mismatch

A pharmacokinetic mismatch is built into the KLOW co-formulation. BPC-157 has a short elimination half-life — approximately 20–30 minutes in formal PK work. The tripeptides KPV (MW 342 Da) and GHK-Cu (MW 402 Da) are small molecules expected to clear even faster as free tripeptides in circulation, though their tissue-selective uptake via PepT1 may extend local activity at inflamed sites. Native thymosin beta-4 has shown dose-proportional PK with longer half-life at higher IV doses in the Phase 1 study [9]; data for the TB-500 fragment specifically are not available.

The practical consequence is that a single co-formulated dose cannot keep all four components at comparable exposures simultaneously. Whether this matters for tissue-repair outcomes — whether sequential availability at different concentrations is neutral, beneficial or counterproductive — is an untested question. The blend's frequency of use in the research-community context is typically described in general terms ('every few days' or 'several times per week') without validated evidence to support any specific interval.

## Reconstitution and stability context

KLOW is supplied as a lyophilized (freeze-dried) powder. For laboratory research handling, it is reconstituted with bacteriostatic water. The reconstituted solution is typically refrigerated. Copper(II) in GHK-Cu can participate in redox chemistry; co-dissolving it with three other peptides in one vial raises a theoretical compatibility and oxidation consideration that has not been formally characterized for this mixture [4, 5]. This is a structural chemical concern, not a documented degradation outcome.

## Routes studied in the component literature

The component literature covers several administration routes across different compounds and applications:

- **Subcutaneous injection** is the most common research-handling route for all four components
- **GHK-Cu**: topical (extensive clinical cosmetic data) and intraperitoneal (rodent studies) [4]
- **KPV**: oral in mice (drinking water); intraperitoneal in mice; cell-culture in vitro [3]
- **BPC-157**: intraperitoneal in rodents; intra-articular in humans (case series); IV in the 2025 safety pilot [2, 6, 11]
- **TB-500 / thymosin beta-4**: topical and intraperitoneal in rodents; intravenous in the Phase 1 study [1, 9]

No formal route-comparison study exists for the KLOW co-formulation. The component literature's route data are not transferable to a blend without blend-specific PK work.

---

Four lit nodes traced along their own studies — an indigo-circuit reading of the peer-reviewed component record, with every gap kept open.